ProCE Banner Events

Share

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care

Live satellite symposium with a panel of experts discussing current guidelines and latest clinical evidence for the management of patients with multiple myeloma including expert guidance to help inform treatment decisions and therapy sequencing.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Evaluation link: https://education.nccn.org/MyelomaChicago2025

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Registered Nurses: 1.50 Nursing contact hour

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Who Should Attend

This activity is intended for hematologists, oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Time and location

Saturday, May 31, 2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Salon A5

Agenda

Registration and Dinner: 6:30 PM - 7:00 PM CT

Symposium: 7:00 PM - 8:30 PM CT

 

Welcome, Baseline Assessment, Introduction  

I. Overview and Unmet Needs and Disparities in MM

  • Diagnosing and risk stratification of smoldering myeloma
    • Rationale and data for treating high-risk smoldering myeloma
  • Modest vs aggressive treatment: What approach should be taken?
  • NCCN Guidelines recommendations
  • SLIM-CRAB criteria for diagnosis of MM

II. MM Confirmed: What Are Next Steps for Optimal Treatment of ND MM?

  • Risk stratification and the role of genetic abnormalities
  • Approaches to transplant-eligible patients
  • Approaches to transplant-eligible and transplant-ineligible patients
  • NCCN Guideline recommendations
  • ASCO 2025 data highlights

III. Updates on New Treatment Options for Previously Treated MM:  Optimizing Therapy Sequencing in R/R MM

  • Strategies at first relapse: factors influencing treatment selection in previously treated MM
    • Treatment of MM that is triple-class refractory
  • CAR T-cell therapy: A big step forward in targeting BCMA

IV. Hot Topics: Addressing Key Questions and Controversies

  • Which NCCN Guideline updates are the most critical to implement right now?
  1. Closing Remarks: The New Algorithm for MM Treatment
  2. Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Room Name

Salon A5

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma. 

Target Audience
This activity is intended for hematologists, oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN Guidelines, risk assessment, comorbidities, and patient age/fitness and preferences
  • Select optimal sequencing and bridging therapies for patients with relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN Guideline recommendations and response to and tolerance of previous therapies
  • Appraise the latest clinical data for current and emerging therapies/regimens for patients with multiple myeloma
  • Implement strategies to improve access, quality of care, and equitable clinical trial enrollment for all patients with multiple myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-25-044-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

CCO 2022
NCCN 2020

Supporter

Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Sanofi.

Sanofi

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Partner

Clinical Care Options, LLC

Clinical Care Options, LLC

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.